These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
90 related items for PubMed ID: 15650493
21. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Nakajima M, Terao T, Iwata N, Nakamura J. Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461 [Abstract] [Full Text] [Related]
22. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Paparrigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C. Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan 30; 31(1):92-6. PubMed ID: 16938372 [Abstract] [Full Text] [Related]
23. Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia. Lawford BR, Barnes M, Connor JP, Heslop K, Nyst P, Young RM. J Psychopharmacol; 2012 Feb 30; 26(2):324-9. PubMed ID: 21262859 [Abstract] [Full Text] [Related]
24. Hyperprolactinemia associated with psychotropics--a review. Madhusoodanan S, Parida S, Jimenez C. Hum Psychopharmacol; 2010 Feb 30; 25(4):281-97. PubMed ID: 20521318 [Abstract] [Full Text] [Related]
25. Prolactin response to neuroleptics. Clinical and theoretical implications. Ohman R, Axelsson R. J Neural Transm Suppl; 1980 Feb 30; 17():1-74. PubMed ID: 6133911 [No Abstract] [Full Text] [Related]
30. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series. Kawabe K, Horiuchi F, Ueno S. Clin Neuropharmacol; 2013 Dec 30; 36(6):239-41. PubMed ID: 24201238 [Abstract] [Full Text] [Related]
32. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Roke Y, van Harten PN, Franke B, Galesloot TE, Boot AM, Buitelaar JK. Pharmacogenet Genomics; 2013 Sep 30; 23(9):487-93. PubMed ID: 23851570 [Abstract] [Full Text] [Related]
33. An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. Einarson TR, Hemels ME, Nuamah I, Gopal S, Coppola D, Hough D. Ann Pharmacother; 2012 Oct 30; 46(10):1322-30. PubMed ID: 22947594 [Abstract] [Full Text] [Related]
35. Use of antipsychotics in children and adolescents. Findling RL, Steiner H, Weller EB. J Clin Psychiatry; 2005 Oct 30; 66 Suppl 7():29-40. PubMed ID: 16124839 [Abstract] [Full Text] [Related]
36. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. Varley CK, McClellan J. JAMA; 2009 Oct 28; 302(16):1811-2. PubMed ID: 19861677 [No Abstract] [Full Text] [Related]
37. Female puberty: clinical implications for the use of prolactin-modulating psychotropics. Becker AL, Epperson CN. Child Adolesc Psychiatr Clin N Am; 2006 Jan 28; 15(1):207-20. PubMed ID: 16321731 [Abstract] [Full Text] [Related]
39. The influence of neuroleptic drugs on prolactin secretion in children. Gualtieri CT, Rojahn J, Staye J. Dev Med Child Neurol; 1980 Aug 28; 22(4):515-8. PubMed ID: 6105985 [No Abstract] [Full Text] [Related]